Currently Viewing:
Kidney Week 2019
Time to Focus on Increasing Organs for Patients With ESRD, Azar Says at Kidney Week
November 07, 2019
Dr Tammy Brady Discusses the Role of the Pediatric Nephrologist on the Care Team for Metabolic Syndrome
November 07, 2019
Dr Danielle Kirkman Explains How Exercise Testing in Patients With CKD Can Improve Care
November 07, 2019
Dr Cynthia Delgado on the Importance of Patient Input in Kidney Disease Care
November 08, 2019
Data From 3 Roxadustat Trials Lead Off Kidney Week Sessions Ahead of Efficacy, Safety News
November 08, 2019
Currently Reading
Dr Joseph Vassalotti Presents Findings of AJMC® Study on CKD Intervention
November 08, 2019
Researchers Develop Tool to Identify Those at Risk of Future CKD
November 08, 2019
Paul Conway: Respect, Listening Are Keys to Engaging Patients in Kidney Care
November 08, 2019
Pooled Cardiovascular Data on Roxadustat Show No Increased Risk to Patients With CKD
November 08, 2019
Dr Jay Wish Explains Implications of New Roxadustat Data
November 09, 2019
Patients on Dialysis Have More Hospitalizations in Areas With More Black Residents
November 09, 2019
Physicians, Patient Discuss Intentional Nonadherence in Hypertension Therapy
November 10, 2019
Dr Holly Kramer Discusses Components of the Advancing American Kidney Health Initiative
November 11, 2019
Early Warning Signs of CKD Going Unnoticed in Veterans, Especially Those With Hypertension
November 11, 2019
As Kidney Week Ends, Providers Are Urged to Join New Care Models
November 11, 2019
Understanding More About Quality of Life Impact for Patients With CKD, Anemia
November 11, 2019

Dr Joseph Vassalotti Presents Findings of AJMC® Study on CKD Intervention

A study published in the November issue of The American Journal of Managed Care® provides evidence from an intervention for chronic kidney disease (CKD), explained lead author Joseph Vassalotti, MD, clinical professor at Icahn School of Medicine at Mount Sinai and chief medical officer of the National Kidney Foundation.


A study published in the November issue of The American Journal of Managed Care® (AJMC®) provides evidence from an intervention for chronic kidney disease (CKD), explained lead author Joseph Vassalotti, MD, clinical professor at Icahn School of Medicine at Mount Sinai and chief medical officer of the National Kidney Foundation.

Transcript

What were the findings of your recent AJMC® study on a health plan’s CKD intervention?

The study showed a population health, simple, scalable intervention for chronic kidney disease among people with diabetes and/or hypertension, showed reduction in hospitalizations and readmission and selected cost containment. So we’re really excited that this short-term 2-year study with a pre- and post design showed benefits in chronic kidney disease population health intervention.

Which aspects of the intervention do you think had the greatest effect on outcomes?

The study was designed to incorporate both the blood and urine testing for kidney disease, the estimated GFR [glomerular filtration rate] and the urine albumin-to-creatinine ratio tests, so those are tests of kidney function and kidney damage, and by defining kidney disease according to those tests and stratifying the risk at 5 different levels, we were able to employ a population health that was scaled to the severity of disease in a patient-centered medical home with CareFirst Blue Cross Blue Shield in Maryland.

Why was the intervention successful? So certainly the risk stratification informing the interventions is probably the most important aspect of the study to emphasize. It wasn’t just the kidney function, it was the kidney function by the estimated GFR with the urine albumin-to-creatinine ratio together, and a layered intervention that increased as the severity of the disease increased. The other important aspect of the study was that we did increase the use of medical nutrition therapy for the patients with chronic kidney disease, which is impactful.

And then we allocated the nephrology services in a way that was more consistent with the heat map class, or the severity of the disease. For example, the patients with class 5 on the heat map which are the most severe at risk for adverse events, in the preintervention year, 63% of the patients saw a nephrologist, and the ones that saw a nephrologist saw a nephrologist quarterly. In the postintervention year, 83% of the patients with CKD class 5 saw a nephrologist, and they saw a nephrologist, on average, monthly. So we had intensification of nephrology services for the patients with the most advanced disease, and we didn’t have any increase in nephrology services for patients with lower classes or lower severity of CKD. So, we allocated a finite resource, nephrology services, according to the risk stratification.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up